Reza Shojaei: On The 2nd Day of IPAW 2025, Let’s Focus on Patients, The Real Reason Plasma Matters!
Reza Shojaei, Chief Operating Officer at Canadian Plasma Resources, shared on LinkedIn:
”On the second day of IPAW 2025, let’s focus on patients, the real reason plasma matters.
Plasma-derived medicines treat life-threatening conditions such as primary immune deficiencies, hemophilia, and hereditary angioedema.
For many, these therapies are not optional; they are the only available treatment, turning what used to be fatal diseases into manageable conditions.
Every donation ensures someone, somewhere, gets another chance at health, at family life, at simply living fully.
Behind each unit of plasma is a powerful chain: a donor’s generosity, a patient’s survival, and then a family’s hope.
Let’s use this week to amplify the voices of patients and remind the world that plasma saves lives every single day.
If you know someone whose life has been touched by plasma therapies, share their story on social media, because awareness grows stronger when it’s personal.”

Stay updated on emerging topics in transfusion medicine with Hemostasis Today.
-
Jul 13, 2026, 15:42Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy
-
Jul 13, 2026, 15:23Akshat Jain: 5 Key Clinical Takeaways from ISTH 2026
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at ISTH 2026
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026